Roche collaborates with Blueprint Medicines to bring a new treatment to people with RET-altered cancers

Roche collaborates with Blueprint Medicines to bring a new treatment to people with RET-altered cancers

Roche (Basel, Switzerland) and Blueprint Medicines Corporation announced the signing of a licensing and collaboration agreement providing exclusive rights to Roche for global co-development and commercialization outside the U.S., excluding Greater China.

In the U.S., Genentech, a member of the Roche Group, will obtain co-commercialization rights to pralsetinib, Blueprint Medicine’s investigational, once-daily oral precision therapy for the treatment of people with RET-altered non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC) and other types of thyroid cancer, as well as other solid tumors.

In addition, pralsetinib has demonstrated tumor-agnostic potential. The companies also plan to expand development of pralsetinib in multiple treatment settings and explore development of a next-generation RET inhibitor under the collaboration…

Learn More